VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
CAH
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
CAHCardinal Health, Inc.
$279.25$65.4B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksCAHFinancials

Cardinal Health, Inc. (CAH) Income Statement

30Y historyFree accessUpdated daily

Revenue and margin performance show volatile top-line growth and a gross margin confined to 3.1% to 4.3%, with operating margin improving to 1.1% in the latest quarter on $753M of operating income, though net margin remains thin at 0.8%.

Income StatementBalance SheetCash FlowRatios

CAH Income Statement

Annual statement

CAH Income Statement

Cardinal Health, Inc. (CAH) annual income statement — 30-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMJun'26Jun'25Jun'24Jun'23Jun'22Jun'21Jun'20Jun'19Jun'18Jun'17Jun'16Jun'15Jun'14Jun'13Jun'12Jun'11Jun'10Jun'09Jun'08Jun'07Jun'06Jun'05Jun'04Jun'03Jun'02Jun'01Jun'00Jun'99Jun'98Jun'97
Sales/Revenue257.75B254.25B222.58B226.83B204.98B181.33B162.47B152.92B145.53B136.81B129.98B121.55B102.53B91.08B101.09B107.55B102.64B98.5B95.99B87.41B86.85B79.66B72.67B64.52B56.73B51.14B47.95B38.35B25.11B21.08B18.39B
Revenue Growth %10%14.23%-1.87%10.66%13.04%11.61%6.24%5.08%6.38%5.26%6.94%18.55%12.57%-9.9%-6.01%4.78%4.2%2.62%9.82%0.64%9.02%9.63%12.62%13.73%10.94%6.65%25.03%52.72%19.15%14.58%98.93%
Cost of Goods Sold247.7B244.47B214.41B219.41B198.1B174.84B155.69B146.05B138.7B129.63B123.43B115B96.82B85.92B96.17B103.01B98.48B94.72B92.24B83.63B81.61B74.85B68.21B59.88B52.25B47.09B44.34B35.25B22.25B18.6B16.16B
COGS % of Revenue-96.16%96.33%96.73%96.65%96.42%95.83%95.51%95.3%94.75%94.97%94.62%94.43%94.33%95.13%95.78%95.95%96.16%96.1%95.68%93.96%93.96%93.86%92.8%92.1%92.09%92.47%91.93%88.61%88.24%87.88%
Gross Profit10.05B9.77B8.17B7.41B6.89B6.48B6.78B6.87B6.83B7.18B6.54B6.54B5.71B5.16B4.92B4.54B4.16B3.78B5.53B5.63B5.25B5.28B5.01B4.74B4.51B4.05B3.61B3.13B2.82B1.11B956.2M
Gross Margin %3.9%3.84%3.67%3.27%3.36%3.58%4.17%4.49%4.7%5.25%5.03%5.38%5.57%5.67%4.87%4.22%4.05%3.84%5.76%6.45%6.04%6.63%6.89%7.35%7.95%7.91%7.53%8.17%11.24%5.25%5.2%
Gross Profit Growth %-19.66%10.17%7.62%6.25%-4.34%-1.31%0.5%-4.83%9.73%0.02%14.55%10.68%4.88%8.37%9.11%10.09%-31.59%-1.91%7.41%-0.67%5.48%5.6%5.13%11.46%12.03%15.28%11.02%155.19%15.65%27.87%
Operating Expenses7.35B7.16B5.89B6.17B6.12B7.09B6.31B10.97B4.77B7.05B4.42B4.08B3.55B3.28B3.92B2.75B2.65B2.47B2.46B2.38B3.87B2.97B2.68B2.31B2.3B2.21B2.12B1.82B1.82B1.62B1.51B
OpEx % of Revenue-2.82%2.65%2.72%2.99%3.91%3.88%7.17%3.28%5.16%3.4%3.36%3.46%3.6%3.88%2.56%2.58%2.51%2.56%2.73%4.46%3.73%3.68%3.58%4.05%4.33%4.43%4.73%7.24%7.69%8.23%
Selling, General & Admin6.27B6.13B5.38B5B4.8B4.51B4.53B4.57B4.48B4.6B3.77B3.65B3.24B3.03B2.88B2.68B2.59B2.35B3.44B3.41B3.08B3.2B2.86B2.35B2.23B2.07B2B1.63B1.56B567.8M513.6M
SG&A % of Revenue-2.41%2.42%2.2%2.34%2.49%2.79%2.99%3.08%3.36%2.9%3%3.16%3.32%2.84%2.49%2.53%2.38%3.58%3.91%3.55%4.02%3.94%3.64%3.93%4.06%4.17%4.24%6.23%2.69%2.79%
Research & Development0000000000000000000000000000000
R&D % of Revenue-------------------------------
Other Operating Expenses3M1.03B511M1.17B1.32B2.58B1.77B6.39B294M2.46B649M436M311M248M1.05B72M120M77M126.6M44.1M789.3M86.3M179.8M43.7M48.9M138.6M173.8M106.2M238.2M218.4M209.1M
Operating Income2.7B2.61B2.27B1.24B752M-607M472M-4.1B2.06B126M2.12B2.46B2.16B1.89B996M1.79B1.51B1.31B1.29B1.39B1.37B1.84B1.78B2.33B2.19B1.83B1.49B1.28B1.04B858.1M715.7M
Operating Margin %1.05%1.03%1.02%0.55%0.37%-0.33%0.29%-2.68%1.42%0.09%1.63%2.02%2.11%2.07%0.99%1.67%1.47%1.33%1.34%1.59%1.58%2.32%2.45%3.61%3.85%3.59%3.1%3.34%4.15%4.07%3.89%
Operating Income Growth %-14.86%83.02%65.29%223.89%-228.6%111.52%-298.93%1534.92%-94.06%-13.79%13.79%14.64%89.26%-44.42%18.36%15.84%1.52%-7.54%1.36%-25.54%3.52%-23.53%6.57%19.26%23.31%16.13%22.88%21.44%19.9%143.6%
EBITDA3.67B3.57B3.06B1.95B1.44B85M1.25B-3.19B3.06B1.16B2.84B3.1B2.61B2.34B1.39B2.12B1.83B1.56B1.51B1.61B1.7B2.14B2.08B2.62B2.45B2.08B1.77B1.54B1.28B1.08B924.8M
EBITDA Margin %1.42%1.4%1.38%0.86%0.7%0.05%0.77%-2.08%2.1%0.85%2.18%2.55%2.55%2.57%1.38%1.97%1.78%1.58%1.58%1.84%1.95%2.69%2.86%4.06%4.32%4.06%3.69%4.01%5.1%5.11%5.03%
EBITDA Growth %14.05%16.44%56.94%35.25%1598.82%-93.23%139.4%-204.08%164.25%-59.18%-8.48%18.68%11.43%68.27%-34.2%15.87%17.04%3.16%-6.15%-4.92%-20.85%3.11%-20.7%6.82%18.08%17.51%14.97%20.09%18.93%16.4%177.47%
D&A (Non-Cash Add-back)970M956M790M710M692M692M783M913M1B1.03B717M641M451M459M397M325M313M254M225.8M220M322.1M297.6M295.6M289.5M265.8M243.5M280.6M257M238.2M218.4M209.1M
EBIT2.6B2.52B2.32B1.25B747M-637M503M-3.53B2.04B101M2.13B2.45B2.11B1.93B1.01B1.79B1.61B1.32B1.41B1.44B1.52B1.92B1.91B2.41B2.33B1.97B1.49B1.28B1.04B858.1M715.7M
Net Interest Income-341M-348M-215M-51M-84M-147M-180M-238M-294M-329M-201M-178M-141M-133M-123M-95M-93M-113M-114.4M-136.1M00000000000
Interest Income0000000000000000000000000000000
Interest Expense341M348M215M51M84M147M180M238M294M329M201M178M141M133M123M95M93M113M218.7M136.1M00000000000
Other Income/Expense-434M-439M-174M-42M-89M-177M-149M326M-309M-354M-196M-183M-194M-87M-108M-94M4M-95M-127.6M-97.3M-121.4M-104.5M-117.8M-106.8M-106.3M-132.5M-154.9M-138.7M-256.8M-166.7M-176M
Pretax Income2.26B2.17B2.1B1.2B663M-784M323M-3.77B1.75B-228M1.92B2.28B1.97B1.8B888M1.7B1.52B1.21B1.67B1.95B1.25B1.83B1.63B2.24B2.13B1.7B1.33B1.08B759.2M402.5M312.3M
Pretax Margin %0.88%0.86%0.94%0.53%0.32%-0.43%0.2%-2.47%1.2%-0.17%1.48%1.87%1.92%1.97%0.88%1.58%1.48%1.23%1.74%2.23%1.44%2.3%2.24%3.47%3.75%3.33%2.78%2.81%3.02%1.91%1.7%
Income Tax457M469M532M348M332M153M-289M-79M386M-487M630M845M755M635M553M628M552.1M624.6M524.2M633.9M412.6M577.1M586M706.7M699.5M575M474.8M424M302.9M242.9M204.9M
Effective Tax Rate %20.19%21.57%25.32%28.98%50.08%-19.52%-89.47%2.09%22.04%213.6%32.74%37.13%38.38%35.32%62.27%36.98%36.36%51.55%31.45%32.51%32.95%31.45%35.97%31.57%32.89%33.8%35.64%39.34%39.9%60.35%65.61%
Net Income1.82B1.71B1.56B852M330M-938M611M-3.69B1.36B256M1.29B1.43B1.22B1.17B334M1.07B959M642.2M1.15B1.3B1.93B1B1.05B1.47B1.41B1.06B857.4M679.7M456.3M247.1M181.1M
Net Margin %0.71%0.67%0.7%0.38%0.16%-0.52%0.38%-2.42%0.94%0.19%0.99%1.17%1.19%1.28%0.33%0.99%0.93%0.65%1.2%1.49%2.22%1.26%1.45%2.29%2.48%2.07%1.79%1.77%1.82%1.17%0.98%
Net Income Growth %13.98%9.8%83.22%158.18%135.18%-253.52%116.54%-370.95%432.42%-80.12%-9.74%17.45%4.2%249.1%-68.76%11.47%49.33%-44.23%-11.46%-32.65%93.09%-4.82%-28.74%4.89%33.1%23.19%26.14%48.96%84.66%36.44%61.84%
Net Income (Continuing)1.81B1.71B1.57B853M331M-937M612M-3.69B1.36B259M1.29B1.43B1.21B1.16B335M1.07B966M587M758.2M847.2M839.7M1.16B1.07B1.52B1.38B1.13B857.4M717.8M481M448.5M334.8M
Discontinued Operations0000000000003M3M00008.8M-15.3M1.09B0000000000
Minority Interest159M159M147M1M1M3M3M3M2M020M17M0000000000000000000
EPS (Diluted)7.807.236.453.451.26-3.342.08-12.604.530.814.034.323.623.380.973.062.721.773.183.574.772.332.413.353.032.331.851.581.121.020.82
EPS Growth %16.59%12.09%86.96%173.81%137.72%-260.58%116.51%-378.15%459.26%-79.9%-6.71%19.34%7.1%248.45%-68.3%12.5%53.67%-44.34%-10.92%-25.16%104.72%-3.32%-28.06%10.56%30.04%25.95%17.09%41.07%9.8%24.39%60.78%
EPS (Basic)-7.276.483.481.26-3.342.09-12.604.540.824.064.363.663.420.983.102.751.793.223.634.892.382.443.393.082.371.901.611.151.050.84
Diluted Shares Outstanding233M237M242M247M262M279M294M293M301M315M320M330M335M345M344M349M352.5M361.4M361.5M364M404.7M428.5M435.98M429.91M453.83M453.3M463.46M454.3M427.8M416.85M238.4M
Basic Shares Outstanding232M236M241M245M261M279M292M293M300M313M317M327M332M341M341M345M348.6M358.8M357.6M358.2M394.9M421.2M430.61M424.84M446.46M445.65M451.26M445.84M416.55M406.8M233.73M
Dividend Payout Ratio-28.65%31.65%58.57%159.09%-93.78%-42.33%226.95%44.8%35.88%37.86%35.59%105.69%28.06%28.59%39.41%17.4%13.31%7.48%10.18%4.92%3.55%3.19%4.26%4.27%4.41%12.43%4.65%5.02%

Key Metrics

Growth RegimeMixed
ProfitabilityWeak
Balance SheetMixed
Cash FlowMixed
Top Statement Risk

Thin margins amplify volatility

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2027Q1)

Volatile Growth Masks Flat Underlying Momentum

According to the reported quarterly income statements, CAH's revenue has swung between roughly negative 4% and positive 22% year over year across the last ten quarters, indicating growth that is highly sensitive to timing and volume shifts rather than a steady compounding trend.

The quarterly series shows revenue moving from $52.3B to $67.5B, with the strongest prints clustered in fiscal 2026 after several quarters of near-zero or negative growth. This pattern suggests the recent acceleration may reflect a recovery in pharmaceutical volumes and pricing rather than a durable step-change, so investors should monitor whether sequential revenue gains hold through the next two quarters. The trailing growth figure of roughly 299% in the snapshot appears distorted by a weak base and should not be extrapolated.

Razor-Thin Gross Margins Structurally Capped

Based on reported figures, CAH's gross margin has held in a narrow 3.1% to 4.3% band across the ten quarters, confirming a distribution model where cost of products sold consumes roughly 96% of revenue and pricing power is limited.

The stability of the gross margin band suggests that CAH has not materially expanded its spread despite growing scale, which is consistent with a high-volume intermediary role. Gross profit dollars have grown from about $1.9B to $2.6B, but this appears driven by volume rather than margin improvement. Any shift in generic deflation or manufacturer rebate timing would likely move the margin band directly, warranting continued scrutiny.

Modest Operating Leverage Emerging Recently

As reported in the quarterly statements, operating income rose from $408M to $753M while SG&A stayed near $1.2B to $1.6B, suggesting some operating leverage has begun to appear in the most recent periods.

Operating margin improved from about 0.7% to 1.1%, indicating that overhead growth has lagged gross profit growth in fiscal 2026. However, the absolute improvement is small relative to revenue scale, so the leverage appears modest and sensitive to a single quarter. Investors should treat this as an early signal requiring confirmation over multiple periods rather than a proven efficiency gain.

Net Income Lags Operating Gains Persistently

Based on EPS and net income figures, CAH's net margin of 0.4% to 0.9% sits well below its operating margin, and quarterly EPS swings from $0.96 to $2.38 point to meaningful non-operating or tax-related variability.

The gap between operating income and net income in several quarters, such as 2025Q3 where operating income was $730M and net income $506M, suggests interest, tax, or other non-operating items absorb a significant share of operating profit. Stock-based compensation of $30M to $153M per quarter is modest relative to earnings but should be considered alongside any one-time items. The EPS growth figures, including swings of 96% and negative 19.5%, appear to reflect this noise more than underlying earnings power.

Cost of Products Sold Dominates Entire Structure

According to reported figures, cost of products sold consumed roughly 96% of revenue in every quarter, leaving SG&A at about 2.4% to 2.9% of revenue as the only meaningful discretionary cost line.

With R&D reported as zero, the cost base is effectively a binary between product cost and overhead, implying that the company's profitability depends almost entirely on procurement spreads and distribution efficiency. SG&A has grown in dollar terms but has remained a stable share of revenue, which suggests reasonable expense discipline. Monitoring whether SG&A growth stays below revenue growth will be the key test of cost control going forward.

Thin Spreads Leave Little Margin for Error

As reported in the quarterly figures, CAH's net margin of roughly 0.4% to 0.9% leaves minimal buffer, so modest reimbursement pressure or cost inflation could erase recent earnings gains and expose the fiscal 2026 trajectory as partly cyclical.

A bearish reading would argue that the strongest quarters rely on favorable timing, tariff-related recoveries, or rebate movements rather than sustained spread expansion, and that the trailing 299% growth figure reflects a depressed base rather than durable momentum. The company's reported net income of $239M in 2025Q4 against $506M in 2025Q3 illustrates how quickly profitability can swing. Investors should therefore weigh management's constructive tone against the arithmetic of a sub-1% net margin business.

CAH — Frequently Asked Questions

Quick answers to the most common questions about buying CAH stock.

What was Cardinal Health, Inc.'s (CAH) revenue in 2026?

For fiscal year 2026, Cardinal Health, Inc. (CAH) reported total revenue of $254.25B. This represents a 1282.2% increase compared to $18.39B in 1997.

Is Cardinal Health, Inc. (CAH) profitable?

Cardinal Health, Inc. (CAH) is profitable, generating $1.71B in net income for the fiscal year ending 2026 with a net profit margin of 0.7%.

What is Cardinal Health, Inc.'s operating profit margin?

Cardinal Health, Inc. (CAH) reported an operating income of $2.61B, resulting in an operating profit margin of 1.0%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Cardinal Health, Inc.'s gross profit and gross margin?

Cardinal Health, Inc. (CAH) generated $9.77B in gross profit for the year, representing a gross profit margin of 3.8%. This demonstrates the company's core pricing power and production efficiency.